Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezabenlimab combination therapy in advanced solid tumors
NCT03697304Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ezabenlimab in gastric adenocarcinoma, gastro-oesophageal adenocarcinoma (EAC), colorectal cancer (CRC), endometrial carcinoma, solid tumor (advanced stage), sponsored by Boehringer Ingelheim. Started Mar 2019; status: completed.
02
Drugs
ezabenlimab
03
Conditions
gastric adenocarcinomagastro-oesophageal adenocarcinoma (EAC)colorectal cancer (CRC)endometrial carcinomasolid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03697304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03697304.